Emerging Molecular Targets to Treat Disorders Affecting Cognitive Function
Summary
Pharmaceutical Education Associates’ presents a one-of-a-kind forum exploring the most recent and clinically relevant research pertaining to brain targets for the enhancement of cognitive function. Of particular interest will be the effectiveness of new cognition-enhancing drugs in the treatment of neurodegenerative disorders such as Alzheimer’s disease, as well as their potential for the treatment of the cognitive decline associated with normal aging or as a prelude to disease.Emerging Molecular Targets to Treat Disorders Affecting Cognitive Function
The Westin Princeton at
About this ConferencePharmaceutical Education Associates’ presents a one-of-a-kind forum exploring the most recent and clinically relevant research pertaining to brain targets for the enhancement of cognitive function. Leading researchers will share findings obtained from animal models and clinical studies in which drugs have been targeted to cholinergic, glutamatergic, GABAergic, histaminergic, and specific second messenger pathways, as well as KCNQ potassium channels. Of particular interest will be the effectiveness of new cognition-enhancing drugs in the treatment of neurodegenerative disorders such as Alzheimer’s disease, as well as their potential for the treatment of the cognitive decline associated with normal aging or as a prelude to disease.
Among the cutting-edge presentations you’ll hear are:
*Exploring the PDE-4/CREB Pathway
Tim Tully, Therapeutics
*GABA-B antagonists: Preclinical and Clinical Profile of SGS742, a novel GABA-B receptor antagonist
Thorsten Melcher, Saegis Pharmaceuticals, Inc.
*AMPA Receptor Modulation
Gary Rogers, Cortex Pharmaceuticals
*H3 Antagonists: Broad Preclinical Efficacy in Cognition and Schizophrenia
Gerard Fox, Abbott Laboratories
*TC-1734: An Orally Active Neuronal Nicotinic Receptor Modulator and Long-Lasting Cognitive Enhancing Properties and Neuroprotective Properties
Gregory Gatto, Targacept, Inc.
*KCNQ Channels as Potential Targets for the Treatments of Cognitive Diseases
William Dalby Brown, Neurosearch A/S ()
*M1 Muscarinic Agonists: Their Therapeutic Potential in Alzheimer’s Disease (AD) and Related Diseases
Abraham Fisher, Israel Institute for Biological Research,
PLUS: A Special Workshop: “Overcoming the Blood Brain Barrier in CNS Drug Delivery”
Part I: The Blood-brain Barrier and Delivery of Drug and Gene Therapeutics to the CNS
Part II: Intranasal Drug Delivery to the CNS
Presenter, Parts I and II : William H. Frey, II, Alzheimer’s , and
Part III: Peptide Transport Across the Blood-Brain Barrier
Weihong Pan, and VAThis event is truly a must-attend chance to hear the latest research in the rapidly growing field of cognitive enhancing drugs.
To register, call 800-686-2276 or click to register here http://www.pharmedassociates.com/rand.asp#p166